Introduction
Primary percutaneous coronary intervention (PPCI) has become the treatment of choice for ST elevation myocardial infarction (STEMI). However, the optimal anti-thrombotic regimen remains controversial. Early evidence for benefit with glycoprotein inhibitors (GPIs) came from trials such as ADMIRAL, CADILLAC, and ISAR 2.
1 A meta-analysis from 2005 involving almost 4000 patients treated with abciximab in eight PPCI randomized controlled trials (RCTs) showed significant short-and long-term mortality benefits 2 Studies on other GPIs suggested similar benefits. 3 However, later studies challenged their continued relevance in modern practice. For example, BRAVE-3 suggested that benefits of abciximab in STEMI were negated when higher loading doses of clopidogrel were used. 4 The place of GPIs was further questioned by the results of HORIZONS. 5 Early and late mortality benefits were found with bivalirudin, compared with a heparin-plus-routine GPI combination, with a 30-day absolute mortality difference of 1% (relative risk 0.66). The mechanisms by which bivalirudin achieved these mortality benefits remain unclear and several issues are noteworthy. Firstly, the earlier incidence of stent thrombosis with bivalirudin (with later catch-up in the other treatment arm) was postulated to be relevant (since in-hospital complications might be more rapidly, and hence more successfully, addressed)-however, a later HORIZONS sub-study did not support this explanation. 6 Secondly, the other main candidate mechanism for benefit was via the demonstrably lower rate of bleeding in patients receiving bivalirudin-however, the means by which early bleeding problems led to survival curves that were still diverging beyond 1 year is uncertain. Finally, and even more intriguingly, a recently published analysis from HORIZONS indicates that the mortality benefits of bivalirudin over heparin-plus-GPI were evident even when patients with major bleeds were excluded. 7 This led to speculation about additional, ill-defined pleiotropic actions of bivalirudin. This mortality advantage appeared to be restricted to patients with the highest blood leucocyte counts, for unknown reasons. 8 Subsequent studies comparing bivalirudin with other anti-thrombotic strategies (including EuroMax, BRIGHT, HEAT PPCI, and most recently MATRIX) have produced inconsistent mortality findings (see Discussion for details). 9 -12 This has led to considerable uncertainty regarding potential survival benefits with bivalirudin use compared with other therapies in PPCI.
The diversity of clinical practice in the UK permits the study of three broad anti-thrombotic combinations in primary PCIbivalirudin, heparin-with-GPI, and heparin alone. We sought to investigate patterns of use and their association with outcomes, using the United Kingdom National Registries for PCI procedures and mortality.
Methods

UK National percutaneous coronary intervention database
Data on PCI in the UK are compiled under the auspices of the National Institute of Cardiovascular Outcomes Research (NICOR) and the British Cardiovascular Intervention Society (BCIS). The dataset is composed of 113 variables, including patient demographics and procedural details. Mortality tracking is undertaken annually using the patients' unique National Health Service numbers to link the BCIS-NICOR database to that held by the UK Office of National Statistics (ONS), on which all UK deaths are recorded. This tracking is not available for patients in Scotland or Northern Ireland. Details on data capture, handling and validation in the registry have been published previously. 13 
Study population
Study subjects were those patients who underwent a PPCI procedure for STEMI in the UK between 1 January 2008 and 1 January 2012. This time period was chosen since it reflects an era of 'contemporary STEMI management' in which, for example, high dose oral antiplatelet loading was routinely used pre-procedure and radial access was utilized in a significant proportion of cases.
Outcome measures
The primary outcome measure for this study was 30-day mortality. Secondary endpoints were 1-year mortality, time to death (survival curve analysis), and in-hospital major bleeding. Major bleeds comprised gastrointestinal bleeds, intracerebral bleeds, retroperitoneal bleeds, blood or platelet transfusion, or an arterial access site complication requiring surgery. Major bleeding events were obtained from recorded entries on the BCIS-NICOR database-recording is dependent on appropriate completion of the relevant field on the database (concerning PCI complications) by clinical staff, either at the time of the PPCI procedure (for early bleeds) or subsequently (for delayed bleeds). This field is not cross-populated from another database (in contrast to mortality data).
Study definitions
Patients were coded into three treatment groups based on physicianallocated therapy at time of STEMI. These groups were (i) bivalirudin, (ii) heparin alone (i.e. without accompanying GPI or bivalirudin), (iii) heparin-plus-GPI. Patients who received bivalirudin plus heparin were coded within the bivalirudin group. Patients who received both bivalirudin and a GPI were also coded within the bivalirudin group (since they were considered likely to represent an initial bivalirudin strategy with bail-out GPI).
Statistical methods
Descriptive statistics
For basic analysis of patient demographics, procedural characteristics and unadjusted outcomes, continuous variables were evaluated as means + SD. Means, standard deviations, and percentages quoted refer to numbers within the cohort where data were available. Chi-square tests were used to assess the significance of differences in proportions between groups for categorical variables. Student's t-testing was used for continuous variables. Log-rank testing was used for survival curve analysis. All statistical tests were two-tailed and P , 0.05 was taken as significant.
Imputation
To reduce inherent bias from complete case-only analysis, missing values were addressed by a standard technique of multiple imputation, performed using the MI and MIANALYZE procedures of the statistical software SAS (version 9.2).
Multivariable logistic regression modelling
Since the primary endpoint was binary, a standard logistic regression model was employed. The model was constructed by fitting it first to treatment allocation alone and then by adding each of the variables of interest to the model individually. Variables of interest were selected to encompass known or potential predictors of 30-day mortality, and included: age, gender, weight, diabetes, hypertension, smoking, cerebrovascular disease (transient ischaemic attack or stroke), peripheral vascular disease (PVD), renal impairment (defined as serum creatinine .200 mmol/L or on dialysis), warfarin use, cardiogenic shock, previous myocardial infarction (AMI), previous PCI, previous coronary artery bypass grafting (CABG), Q wave on ECG, and procedural details [including year of procedure, route of access, use of a novel potent oral antiplatelet agent (i.e. prasugrel or ticagrelor), left main stem (LMS) culprit lesion, use of thrombectomy, and intra-aortic balloon pump (IABP) use]. Type of stent [drug eluting stent (DES) vs. bare metal stent (BMS)] was also included since it typically appears as an independent predictor of mortality in registry studies of PCI, almost certainly reflecting selection bias on the part of operators. Hence stent type may be considered a surrogate marker for other unrecorded or unquantified comorbidities (including frailty) and its use as regressor within the model should help to mitigate the influence of unmeasured confounders. Variables found to be significant (P , 0.05) on univariate analysis were put forward into a multivariable logistic regression.
Propensity analysis
As an alternative method for addressing the potential confounding factors due to non-randomized treatment allocation, propensity matching was employed in a separate analysis. Propensity scores were derived for each patient, based on the estimated probabilities of that patient being assigned to each of the treatment groups, given the values of various predictor variables for treatment allocation. The propensity score was then obtained using a multinomial regression model. The predictors for treatment allocation were chosen as those measurable variables that were likely to influence which of the three treatments under consideration was chosen by the operator. Hence factors associated with increased bleeding risk (and therefore appearing on standard bleeding risk scores 14 ) were included, with the full list of variables used as shown for the multivariate analysis (section c) above. In order to undertake propensity matching involving more than two treatment groups, the method described previously by Spreeuwenberg et al. was employed. 15 This used logistic regression with 30-day mortality as the response, with regressors consisting of the propensity scores p1, p2 and their product p1p2, as well as the three treatments. Standard checks for overlap of propensity scores between the treatment arms, and subsequently for the balance of covariates, were performed (see Supplementary material online). Multivariable logistic regression modelling and propensity analysis modelling were performed at 30-day and 1-year post-PPCI time-points, involving those patients on whom there was available mortality data at the respective time-points.
Results
Patient numbers, baseline demographics, and procedural details
The summary of case numbers is shown in Figure 1 . The lower proportion of tracked mortality data for the heparin-plus-GPI group reflected high use of this strategy in Scotland, where database linkage to mortality outcomes post-discharge was not possible. Baseline clinical demographics are displayed in Table 1 . It was noted that the heparin-only treatment group contained patients with a significantly greater incidence of risk factors for adverse outcome compared with the other two treatment arms-specifically, greater age; more frequent diabetes, hypertension, smoking history, peripheral vascular disease, cerebrovascular disease, and significant renal impairment; poorer New York Heart Association (NYHA) class at baseline; more prior myocardial infarction and prior CABG, and greater concurrent use of warfarin.
Procedural details are given in Table 2 . Patients presenting with shock were found in highest proportion in the heparin-plus-GPI group. In contrast, use of radial access, a thrombectomy device, DES, and novel oral antiplatelet drugs (prasugrel or ticagrelor) was found in the highest frequency in the bivalirudin group.
Unadjusted mortality
Unadjusted mortality data for the three treatment groups are presented as a Kaplan -Meier plot in Figure 2 . Short-and medium-term mortalities were markedly higher in the heparin-only treatment group. Log-rank testing confirmed significantly poorer unadjusted survival for heparin-only patients (P , 0.0001 for heparin-only vs. other two groups). For bivalirudin vs. heparin-plus-GPI, the log-rank test gave P ¼ 0.22, indicating no significant evidence that survival time distributions differed between these two treatment groups.
Major bleeding
Database-recorded rates of in-hospital major bleeding were 38/4158 (0.91%) for bivalirudin, 273/35129 (0.78%) for heparin-plus-GPI, and 110/21849 (0.5%) for heparin alone. Of the 38 patients on bivalirudin who had a major bleed, three patients had received a GPI and 35 patients received heparin. Of the 4120 bivalirudin patients who did not have a major bleed, 600 were on a GPI and 3520 were on heparin. Glycoprotein inhibitor use was not significantly different between those in the bivalirudin group who did and did not have a major bleed (P ¼ 0.25, x 2 test).
Multivariable logistic regression model for 30-day and 1-year mortalities
Thirty-day mortality data were available for 54 514 patients (breakdown by treatment shown in Figure 1 ). Following univariate logistic regression and backward stepwise elimination, the following variables remained significant and were thus included in the multivariable regression model: age, gender, diabetes, hypertension, smoker/ex-smoker, cerebrovascular disease, peripheral vascular disease, renal impairment, year of procedure, previous PCI, Q waves, access site, shock, left main lesion, stent type (DES or BMS), IABP use, use of prasugrel or ticagrelor, and treatment allocation groups (bivalirudin, heparin-plus-GPI, and heparin-only, with one of these acting as the reference level). The association of treatment allocation with 30-day mortality is indicated by the Forest plot in Figure 3A . The bivalirudin and heparin-plus-GPI groups showed very similar results, while heparin-only patients showed significantly higher mortality. The odds ratios and 95% CI boundaries were as follows (comparisons shown in the form x:y, with y acting as the reference) bivalirudin: heparin/GPI-OR 1.01 (95% CI 0.84 -1.21), P ¼ 0.92; heparin-only: heparin/GPI-OR 1.24 (95% CI 1.13 -1.35), P , 0.0001 and heparin-only: bivalirudin-OR 1.23 (95% CI 1.02 -1.47), P ¼ 0.026.
Results 1-year post-PPCI are shown graphically in Figure 4A . The parsimonious model contained similar variables to that derived for 30-day mortality, with the addition of weight and previous MI, and the exclusion of smoking, hypertension, and gender. Patterns remained essentially unchanged from those seen at 30 days. The odds ratios and 95% CI boundaries at 1 year were bivalirudin: heparin/GPI-OR 0.96 (95% CI 0.83-1.11), P ¼ 0.59; heparin-only: heparin/GPI-OR 1.28 (95% CI 1.19-1.37), P , 0.0001; and heparin-only: bivalirudin -OR 1.33 (95% CI 1.15-1.54), P , 0.0001. Figure 3A , it is seen that these two distinct modelling methods produced strikingly similar findings. Patterns seen at 30 days post-PPCI remain evident at 1 year. The odds ratios and 95% CI boundaries at 1 year were bivalirudin: heparin/GPI-OR 0.96 (95% CI 0.84-1.10), P ¼ 0.57; heparin-only: heparin/GPI-OR 1.24 (95% CI 1.16 -1.32), P , 0.0001; and heparin-only: bivalirudin-OR 1.29 (95% CI 1.13 -1.47), P ¼ 0.0002. 
Discussion
Rationale for present study
Our study employed the UK national registry of PCI to analyse patterns of practice and address areas of continuing controversy in STEMI management. HORIZONS had a profound impact on the management of STEMI patients, in part due to its findings of reduced mortality with bivalirudin. This led to changes in European and American guidelines. 16 The HORIZONS findings on mortality were supported by an analysis of STEMI patients in the US PREMIER registry but follow-up in this latter work only covered index hospital admissions and hence early post-discharge events would have been missed. 17 In contrast, the EuroMax trial studied 30-day outcomes, finding a significant reduction in the composite of death plus major bleeding (driven by the latter), favouring bivalirudin over a strategy in which heparin was used in combination with a GPI in the majority (69%) of cases. 9 A patient-level pooled analysis of HORIZONS and EuroMax did not demonstrate any significant reduction in all-cause mortality with bivalirudin use (with bail-out GPI) vs. heparin + GPIs. 18 Consistent findings followed from the multicentre Chinese BRIGHT study, with non-significant changes in mortality despite significant reductions in major bleeding with bivalirudin vs. heparin-plus-GPI. 10 No study yet has been adequately powered to definitively address mortality effects and this question remains unresolved. Another contentious issue is the role for a 'heparin-only' strategy (i.e. without planned concomitant GPI or bivalirudin) in primary PCI. The HEAT PPCI trial recently addressed this in an all-comers RCT (using GPIs only for bail out, in both arms) and found heparin yielded similar bleeding rates but significantly fewer ischaemic events (stent thrombosis or reinfarction) compared with bivalirudin at 30 days. 11 The impact of these findings on mortality remains unclear, although a non-significant absolute mortality difference of 0.8% (favouring the heparin group) was noted. In contrast, BRIGHT reported a borderline significant reduction in net adverse clinical events with bivalirudin (driven by reduced bleeding) but no difference in mortality between heparin-only and bivalirudin treatment groups. Most recently, data have been presented from the European MATRIX study in over 7000 patients with acute coronary syndromes (including STEMI). 12 There was no evidence of significant reduction in a composite major adverse cardiovascular events primary endpoint with bivalirudin vs. heparin, + GPI (used in 4.6 and 26% of cases, respectively). It did however find significant reductions in bleeding and in all-cause mortality. MATRIX is the first RCT since HORIZONS to suggest an all-cause mortality benefit with bivalirudin use. However, as with HORIZONS, an important caveat is that the apparent advantage with bivalirudin over heparin, in terms of bleeding, is likely driven (at least in part) by the differential GPI use between comparator arms. However, whether this explains the mortality signal favouring bivalirudin in these two studies remains unclear. We therefore analysed the UK national database of primary PCI to explore this specific issue further.
Patient demographics and treatment allocation
Review of patient demographics and treatment allocation in our study population showed that many patients receive heparin alone. These patients tended to be older, and have more comorbidities. This may reflect the view that giving heparin alone would be considered a safer option than use of heparin-plus-GPI in patients felt to be at higher risk of bleeding (particularly relevant to operators who do not use bivalirudin). The greater incidence of unfavourable patient characteristics in the heparin-only group is likely to be (at least) partly responsible for the poorer unadjusted outcomes of this group-these adverse traits are only partially quantifiable and incompletely captured in the BCIS dataset (in common with other registries); hence, important differences (such as patient frailty) might not be reconciled even when advanced statistical methods were employed in adjusted analyses. Heparin-plus-GPI tended to be used in patients at relatively lower risk of bleeding (lower age, less renal dysfunction, fewer females, etc.). Some differences were also seen in baseline demographics and procedural characteristics between the bivalirudin and heparin-plus-GPI cohorts. It is noteworthy that the use of either prasugrel or ticagrelor was most common in the bivalirudin group, and then more common in the heparin-only group compared with those treated with both heparin and a GPI. It is conceivable that operators felt the benefits of a GPI were fewer when these new antiplatelet drugs (rather than clopidogrel) were used. Operators who elected to use bivalirudin were also more likely to incorporate other recent developments in PCI, such as radial access and thrombectomy devices. Hence, it is certainly plausible that operators choosing bivalirudin might be 'early adopters' of other PPCI innovations. However, an alternative and equally plausible explanation relates to the higher proportion of bivalirudin use during the latter part of the time period under consideration, when these other PCI developments were also being incorporated more frequently into clinical practice. Of course, both explanations may be valid, since they are not mutually exclusive. Importantly however, the influence of all these potentially confounding factors (i.e. other aspects of PPCI treatment and the year of treatment itself) should be mitigated through their inclusion as covariates in both our logistic regression and propensity-based analyses.
Association of anti-thrombotic choice and outcomes
There was a close similarity between the unadjusted survival curves for the bivalirudin and heparin-plus-GPI groups. Thirty-day mortality was 5.1 and 4.6%, respectively, from our data-if there had been an underlying absolute difference of 1% in mortality between these two received-treatment groupings, we calculate that our sample size gave 78 -81% power to detect this as a significant difference between groups (at P , 0.05). Of course, the unmatched nature of these non-randomly assigned groups makes it impossible to directly infer the impact of anti-thrombotic therapy from this non-significant difference. In order to gain insight into the potential underlying effects on mortality of these alternative received-treatments, two different forms of statistical modelling were employed. The findings of the two different models strongly concurred. Neither model provided evidence for a mortality difference at 30 days between bivalirudin and heparin-plus-GPI inhibitor groups. This signal is thus consistent with that from the strategy comparisons performed in the RCTs EuroMax, BRIGHT and also ISAR REACT 4 (which examined a high-risk NSTEMI setting). 9, 10, 19 One of the most potent messages from HORIZONS was an improved survival with bivalirudin in STEMI, which helped to drive practice change internationally (towards greater use of this drug). However, this does not appear consistent with the overall published experience to date and our findings are consistent with a pooled analysis of recent randomized studies indicating no survival difference with these contrasting anti-thrombotic options. 20 Even after statistical adjustment, the heparin-only group in our work fared less well. As discussed above, it is certainly possible that adjustments (based, by necessity, only on captured and quantified variables) may not compensate for all differences between groups-hence an incompletely reconciled higher baseline risk in the heparin-only group might explain the higher mortality seen. However, the results do raise an alternative possibility, namely that a decision to use heparin on its own (possibly due to fear of bleeding problems) might increase the risk for an adverse cardiovascular outcome. This result would of course be contrary to the message emerging from HEAT PPCI and hence it is worth considering why this might be so. 11 In this regard, it might be highly relevant that almost 90% of patients in HEAT PPCI received a potent novel oral antiplatelet agent (prasugrel or ticagrelor) compared with a far lower proportion (13.8%) in our heparin-only group. It is thus plausible that the lack of concomitant use of either a novel oral antiplatelet agent or an intravenous GPI in the vast majority of these patients leaves them with insufficient platelet inhibition during this early window, i.e. during, and in the hours immediately after, PPCI. This might, in turn, translate into increased adverse events with a consequent impact on survival.
Limitations
Being derived from a real-world PCI registry, this paper incorporates 'all-comers' undergoing primary PCI for STEMI, avoiding selection and screening bias against high-risk patients (as is frequently encountered in RCTs). The registry represents daily practice and contributes to the overall knowledge base, alongside data from carefully controlled trials. However, a number of caveats and limitations must be borne in mind to allow appropriate reader interpretation of our presented findings.
(1) Common to all registry-based work, it is recognized that no statistical modelling can fully compensate for unidentified or unmeasured confounding factors that may be imbalanced between non-randomly allocated treatment groups. We recognize that the presence of such confounders may therefore also have potentially influenced comparisons in our work. (2) A second noteworthy issue is that comparisons were made between groups based on received anti-thrombotic treatments. This is intrinsically different to a comparison of treatment protocols-for example, the database does not allow differentiation between GPI use being planned vs. bail out. Hence, the heparin-plus-GPI group in our work will include patients managed with both of these strategies (planned use and bail-out use) and hence is somewhat heterogeneous. A further source of heterogeneity arises from between-centre and between-operator differences in protocols for the use of alternative anti-thrombotics-for example, in centres where bivalirudin is available, it may be the default choice for some operators, while being used more selectively (only in higher bleeding risk cases) by others. In contrast, at centres where bivalirudin is not available, heparin-only is likely to be the selected strategy for high bleeding risk cases. Nevertheless, we strongly feel that our analysis by received-treatment provides useful new information, but it should not be misinterpreted as a comparison of upfront treatment strategies. (3) As the BCIS registry is not monitored at the point of data entry, mis-or under-recording of the anti-thrombotic used is, of course, possible. However, we believe that any such underrecording would be entirely unintentional and very unlikely to introduce any important systematic bias in favour of any particular anti-thrombotic treatment. (4) The low recorded major bleeding rates reflect a combination of (i) the BCIS definition of major bleeding (see Methods), which differs from contemporary trial definitions, making direct comparisons difficult, and (ii) the possibility of under-recording of bleeding problems by operators, since this requires retrospective logging of events. This bleeding event registration contrasts with the robustness of our mortality data taken from the UK Government's ONS. (5) Neither dosing of anti-thrombotic used nor ACT values achieved are recorded in the BCIS-NICOR registry. Usual UK practice is consistent with European and US guidelines with usual initial unfractionated heparin dose in the range 70 -100 units heparin/kg without GPI and 50 -70 units heparin/kg when used with GPI. 21 
Conclusions
In summary, our analysis of the UK National PCI database from 2008 to 2012 shows no significant difference in short-or medium-term mortality between groups treated with bivalirudin vs. heparin-plus-GPI in primary PCI. Our statistical modelling suggests that previously described mortality benefits of bivalirudin over heparin-plus-GPI are not evident in contemporary practice. Further RCTs of different regimens in the current era are warranted, but our data suggest that the differences in mortality outcomes associated with different regimens might be small. Thus, very large studies might be needed to conclusively settle these issues.
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